COVID-19: Strides Pharma gets DCGI nod to conduct favipiravir trials in India
Favipiravir is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014
Bengaluru: Pharmaceutical company Strides Pharma Science said on Thursday it has received regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19.
The Bengaluru-based company has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides founder and non-executive chairman Arun Kumar said on a post-earnings conference call, without giving any more details.
Strides' announcement comes after Glenmark Pharmaceuticals said last month it became the first pharma company in the country to get the nod to conduct favipiravir trials. The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.
Favipiravir is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014.
However, on Wednesday, Kyodo News reported that so far there has been no clear evidence of efficacy for Avigan in treating the novel coronavirus in some clinical trials.
Strides late on Wednesday posted a fourth-quarter consolidated net loss of Rs 207 crore ($27.35 million), as it made a Rs 113 crore write-down of inventory and other expenses related to withdrawal of ranitidine products.
The company's shares rose as much as 5.3 percent to a two-week high in early trade, but pared some gains and were last up 1.8 percent at 10 am.
